学術論文　2014

  1. Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N, Suzuki S, et al. Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study. Oncology 2014;86:53-62.
  2. Tsuchiya K, Asahina Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, et al. Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl 2014;20:291-297.
  3. Tsuchiya K, Asahina Y, Matsuda S, Muraoka M, Nakata T, Suzuki Y, Tamaki N, et al. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer 2014;120:229-237.
  4. Tanaka T, Kasai H, Yamashita A, Okuyama-Dobashi K, Yasumoto J, Maekawa S, Enomoto N, et al. Hallmarks of hepatitis C virus in equine hepacivirus. J Virol 2014;88:13352-13366.
  5. Takano S, Fukasawa M, Maekawa S, Kadokura M, Miura M, Shindo H, Takahashi E, et al. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation. PLoS One 2014;9:e98718.
  6. Saibara T, Enomoto N, Kaneko S, Chayama K, Sata M, Imawari M, Onishi S, et al. Clinical efficacy of combination therapy with ME3738 and pegylated interferon-alpha-2a in patients with hepatitis C virus genotype 1. Hepatol Res 2014;44:410-419.
  7. Nakanishi H, Kurosaki M, Nakanishi K, Tsuchiya K, Noda T, Tamaki N, Yasui Y, et al. Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy. Hepatol Res 2014;44:319-326.
  8. Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res 2014;44:E360-367.
  9. Matsuura K, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, et al. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type. J Viral Hepat 2014;21:466-474.
  10. Maekawa S, Enomoto N. Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C. J Gastroenterol 2014;49:163-164.
  11. Komatsu N, Yamaguchi T, Tsukui Y, Hayakawa H, Kobayashi S, Kadokura M, Amemiya F, et al. [Case of leptomeningeal carcinomatosis with esophageal carcinoma presenting with neurological signs]. Nihon Shokakibyo Gakkai Zasshi 2014;111:765-772.
  12. Komatsu N, Motosugi U, Maekawa S, Shindo K, Sakamoto M, Sato M, Tatsumi A, et al. Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging. Hepatol Res 2014;44:1339-1346.
  13. Ichikawa S, Ichikawa T, Motosugi U, Sano K, Morisaka H, Enomoto N, Matsuda M, et al. Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte-phase image is a risk factor for hypervascular hepatocellular carcinoma. J Magn Reson Imaging 2014;39:293-297.
  14. Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, et al. Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol 2014;49:1152-1162.